Synairgen’s inhaled COVID-19 treatment included in US trial
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
Read More
Tag: SNG001
Synairgen begins large-scale trial of inhaled COVID-19 treatment
First patient in global trial dosed in the UK
Read More
Synairgen’s SNG001 shows strong promise in COVID-19 trial
The drug significantly cut the risk of developing severe disease and patients were twice as likely to recover versus placebo
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
